Rein Therapeutics
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Rein Therapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT06968845
- Locations
- 🇺🇸
The Lung Research Center, LLC, Chesterfield, Missouri, United States
🇺🇸El Paso Pulmonary Association, El Paso, Texas, United States
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Rein Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT05954988
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
News
Aileron Therapeutics Rebrands as Rein Therapeutics, Focuses on Fibrosis Therapies
Aileron Therapeutics has rebranded to Rein Therapeutics, signaling a sharpened focus on developing treatments for orphan pulmonary and fibrotic diseases.